ライフサイエンスコーパス: viral burden

1 of antiretroviral therapy and reduced tissue viral burden.

2 esting a mechanism to explain this increased viral burden.

3 lso responded to IL-2 resulting in decreased viral burden.

4 al infection while also functioning to limit viral burden.

5 tively infected and contributed to the local viral burden.

6 cally accounted for over 90% of the cellular viral burden.

7 found to harbor less than 1% of the cellular viral burden.

8 and around inflammatory infiltrates and not viral burden.

9 nodes and peripheral blood is a function of viral burden.

10 d be a surrogate marker for a high pulmonary viral burden.

11 hocytic alveolitis reflects a high pulmonary viral burden.

12 the OI-induced pathology, but also limit the viral burden.

13 se transcriptase inhibitors markedly reduced viral burden.

14 depletion of CD4+ thymocytes, apoptosis, and viral burden.

15 ed >5 years) and up to 1.2-fold higher total viral burden.

16 whereby IFN-alpha therapy results in reduced viral burden.

17 rganism, leading to a reduction in its total viral burden.

18 pase-1/11-deficient Mx1 mice, independent of viral burden.

19 ession of AIDS, CD4+ or CD8+ cell counts, or viral burden.

20 s of such therapy on both CD4 counts and the viral burden.

21 ere acute respiratory syndrome coronavirus 2 viral burden.

22 ponses and not simply a function of per-cell viral burden.

23 ile and histology and is not attributable to viral burden.

24 metabolic vulnerability, amplifying SIA and viral burden.

25 ale sex, and non-Hispanic ethnicity, but not viral burden.

26 ups had comparable immune-reconstitution and viral burden.

27 c infections and/or infections with a higher viral burden.

28 cell response, and a significant decrease in viral burden.

29 a in a STAT4-dependent manner to limit early viral burden.

30 errant immune responses and do not depend on viral burden.

31 ion and the inability of the host to control viral burden.

32 gher levels of proinflammatory cytokines and viral burden.

33 lone-13 infection exhibited by mortality and viral burden.

34 ls, with minimal effect on the intracellular viral burden.

35 arly Gag-responsive CD4 events are shaped by viral burden.

36 der children and up to 1.2-fold higher total viral burden.

37 8(+) T cells was ineffective at reducing the viral burden.

38 usted virus-specific CD8 T cells and reduced viral burden.

39 loproteinases is equally crucial in lowering viral burden.

40 tide in this region were associated with low viral burden.

41 ncy, and its absence results in an increased viral burden.

42 cells were noted in patients with the higher viral burdens.

43 C4-deficient mice exhibit heightened viral burdens.

44 sm in the brain, as well as the relative CNS viral burdens.

45 superinfection had no significant effect on viral burdens.

46 s 4.4 months; P = .06) and higher cumulative viral burden (14.2 vs 12.5 log EBV copies/mL; P = .06).

47 n are more likely to have a lower total body viral burden, a homogenous viral population, and preserv

48 cosal lamina propria, thereby decreasing the viral burden, access to susceptible cells, and the chron

49 The reduced viral burden achieved solely with an env-based vaccine s

50 Viral burdens achieved by the two nonneurovirulent virus

51 immunized, immunized animals had a decreased viral burden after challenge with infectious virus, more

52 rovided only modest, transient reductions in viral burden after challenge with virulent, pathogenic S

53 CD8+ T cells are sufficient to reduce early viral burden after HSV-2 infection.

54 sion resulted in clinical disease and higher viral burden after SARS-CoV-2 infection, but little evid

55 oduction, which in turn increased epithelial viral burden, airway smooth muscle growth, and type 2 in

56 ugh mice lacking RNase L showed a higher CNS viral burden and an increased mortality, they were less

57 continued to have decreased cell-associated viral burden and another subject had more than doubled C

58 ure treatment with MAb 201 can alleviate the viral burden and associated pathological findings in a g

59 ed type 2 immune responses with an increased viral burden and blunted responses to MaR1.

60 ols WNV infection by restricting tropism and viral burden and by preventing death of infected neurons

61 ce that therapeutic LAT9997 treatment limits viral burden and characteristic features of severe influ

62 .5.5 infection resulted in similar levels of viral burden and clinical disease in hamsters and the co

63 lizing antibody titers were higher, and lung viral burden and cytokines were slightly lower in mice b

64 The inverse relationship between viral burden and DAT availability further supports HIV-m

65 deficient mice had greater mortality, higher viral burden and defective type I interferon response co

66 Among these, DY-III-281 also reduced viral burden and delayed death in SARS-CoV-2-challenged

67 that influence the risk of HIV transmission, viral burden and disease progression.

68 r how prior flavivirus exposure impacts Zika viral burden and disease.

69 n a multi-prong approach to measuring latent viral burden and efficacy of therapeutic interventions a

70 he importance of tissue macrophages in local viral burden and further implicate roles for CC chemokin

71 of Tim-3 is associated with poor control of viral burden and impaired antiviral immune responses.

72 H1N1 infection, potentially owing to greater viral burden and impaired Treg function, may be a novel

73 survival by reducing weight loss and tissue viral burden and improving clinical score.

74 ure occurs under favorable conditions of low viral burden and in the absence of ongoing high level cy

75 Leptin administration decreased mCMV viral burden and increased mCMV-specific T-cell immunity

76 ted mice with recombinant IL-17A reduces the viral burden and increases survival of mice, suggesting

77 y 6 postinfection, significantly reduces the viral burden and increases survival, suggesting a therap

78 bility of cytotoxic T lymphocytes to control viral burden and influence the outcome of disease, are p

79 tected mice from weight loss and reduced the viral burden and levels of inflammation in the lungs.

80 r SARS-CoV-2 could be effective for reducing viral burden and limiting disease severity.

81 of disease, a higher respiratory SARS-CoV-2 viral burden and lower Receptor Binding Domain and Spike

82 host antiviral genes resulting in decreased viral burden and pathogen-mediated inflammation, ultimat

83 n BA.1 and BA.2 authentic viruses and reduce viral burden and pathology in vivo.

84 Lower viral burden and preservation of immune homeostasis, inc

85 the STAT1-independent pathway controls later viral burden and prevents DEN disease in mice.

86 Despite similar viral burden and production of the macrophage chemoattra

87 loss of hepatic immune cells, higher splenic viral burden and reduction in global antiviral gene path

88 ks later, the mean values of all measures of viral burden and surrogate markers of HIV infection were

89 he viral burst leading to a reduction of the viral burden and survival of the mice.

90 t faster declines in protection against high viral burden and symptomatic infection with BNT162b2.

91 est previous studies have underestimated the viral burden and there is a significant relationship bet

92 ps, and persons with gaps in care had higher viral burden and transmission risk potential.

93 ere found to be strongly correlated with the viral burden and with marker genes of the IFN antiviral

94 However, reduction in viral burden and Zika disease varies depending on the in

95 mice, increased central nervous system (CNS) viral burdens and delayed clearance were observed.

96 1 (HIV-1) variants display exceptionally low viral burdens and do not show evidence of disease progre

97 ells which correlated with persistently high viral burdens and increased levels of CD4+ T-cell apopto

98 ) antigens had higher central nervous system viral burdens and increased mortality rates after infect

99 gnaling is critical to restricting placental viral burdens and protecting against pathologic fetal ou

100 ibody (microMT mice) developed increased CNS viral burdens and were vulnerable to lethal infection at

101 hreshold values during infection (i.e. lower viral burden), and less frequently reported any symptoms

102 in T cell infiltration into the CNS, reduced viral burden, and demyelination comparable to RAG1(-/-)

103 the magnitude of antiviral immune responses, viral burden, and exacerbation severity but were not ind

104 ological details including serum biomarkers, viral burden, and histopathological changes leading to d

105 onsistently linked Alzheimer's disease (AD), viral burden, and inflammation to the onset of HAND in H

106 lates with lung IFN-gamma abundance, but not viral burden, and leads to enhanced susceptibility to se

107 ng Sema7A showed increased survival, reduced viral burden, and less blood-brain barrier permeability

108 o postmortem indicators of HIV encephalitis, viral burden, and presynaptic and postsynaptic neuronal

109 time to death, protracted weight loss, lower viral burden, and slower histologic alteration compared

110 ion - preserved lymph node architecture, low viral burden, and viral expression were found.

111 CD4+ lymphocyte counts and lower plasma HIV viral burdens, and is not limited to those receiving pro

112 high plasma N-Ag level and high respiratory viral burden are associated with development of EPCs in

113 s, but effectiveness and attenuation of peak viral burden are reduced with B.1.617.2.

114 response was correlated with modulations in viral burden as assessed by detection of infectious viru

115 correlated with relative neurovirulence was viral burden as measured by both viral CA protein expres

116 ring after two vaccinations had similar peak viral burden as those in unvaccinated individuals.

117 regulatory T cells (Tregs) generated by high viral burden, as depletion of these cells restored SLECs

118 In the placebo group, a large viral burden at entry or delivery or a positive culture

119 lent) and Fr98/SE (slow disease) had similar viral burdens at 3 weeks postinoculation, suggesting tha

120 ain, WNV-infected CCR5-/- mice had increased viral burden but markedly reduced NK1.1+ cells, macropha

121 rize the upper airways of patients with high viral burden but reduced disease risk or severity.

122 imary mediators of viral clearance, but high viral burden can result in deletion of antigen-specific

123 No protection, assessed by viral burdens, CD4 counts, and time to euthanasia was ob

124 er exceeded that of Fr54, reaching levels of viral burden comparable to that seen for Fr98 (rapid dis

125 excess lung damage despite similar levels of viral burden compared with lean control mice.

126 trated significantly lower respiratory tract viral burden compared with solvent-treated control hamst

127 stinct viral shedding dynamics, and salivary viral burden correlated with COVID-19 symptoms, includin

128 though extensive data suggest that intra-CNS viral burden correlates with both the severity of virall

129 for untargeted metagenomics correlated with viral burden determined by quantitative PCR and showed h

130 Viral burdens did not increase, and actually decreased,

131 Systemic administration of LCB1-Fc reduced viral burden, diminished immune cell infiltration and in

132 CC founder strains produced a broad range of viral burden, disease susceptibility and survival, where

133 eurological disease, weight loss, and severe viral burden during a lethal Zika challenge.

134 aques, which displayed significantly reduced viral burdens during the first 18 weeks postchallenge co

135 proteins can act prophylactically to reduce viral burden early in disease and limit morbidity, even

136 trate ZMPSTE24-deficient mice display higher viral burdens, enhanced cytokine production, and increas

137 bjects who started the study with the higher viral burden experienced greater decreases in viral load

138 reduced early IFN-I production and augmented viral burden facilitating the expansion of natural kille

139 id not exacerbate pulmonary inflammation and viral burdens following IAV infection but protected mice

140 s, they also tolerated substantially greater viral burdens following infection.

141 immunity that, when challenged, had reduced viral burden for both influenza and RSV.

142 infection (hpi), there were 27-75 times more viral burden from Spp lentivirus in the lungs than in ot

143 organs; there were also about 3-5 times more viral burden from Spp lentivirus than from VSV-G lentivi

144 -seropositive subjects, all with significant viral burden (> 50,000 HIV RNA copies/mL plasma), showed

145 ce that therapeutic LAT9997 treatment limits viral burden, hyperinflammation, and lung damage.

146 r minimize immunogenicity and have a greater viral burden.IMPORTANCE The most significant barrier to

147 ected mice resulted in reduced morbidity and viral burden, improved lung compliance, and increased CD

148 te, and nonclassical monocytes) to the total viral burden in 22 human T cell leukemia virus type 1 (H

149 phonuclear neutrophil (PMN) infiltration and viral burden in brain of Opn (-/-) mice were significant

150 n animals and may play a role in controlling viral burden in established infection.

151 S2P6 reduces viral burden in hamsters challenged with SARS-CoV-2 thro

152 have been shown to inversely correlate with viral burden in HIV-1-infected individuals.

153 cessfully improved the ability to manage the viral burden in infected patients.

154 ction compared to WT animals in terms of the viral burden in infected tissues as well as elevated mor

155 itro neutralizing activity and reductions in viral burden in K18-hACE2 or human FcgammaR transgenic m

156 from patients with PBC, suggesting a higher viral burden in lymphoid tissue.

157 ZIKV clinical susceptibility despite reduced viral burden in mice with expanded virus-specific CD8(+)

158 on and the subsequent determination of HIV-1 viral burden in monocytes.

159 ey had more severe immunopathology, enhanced viral burden in multiple organs, and suppression of MCMV

160 virus, and this was associated with greater viral burden in multiple organs.

161 positively correlated with the magnitude of viral burden in naive and central memory CD4(+) T-cell p

162 the central nervous system (CNS) and higher viral burden in neuronal tissues.

163 The mean viral burden in persistently infected immunized macaques

164 and IFNAR1/LR1(-/-) mice had an uncontrolled viral burden in the airways and lung and increased viral

165 and showed enhanced survival rate and lower viral burden in the brain after lethal WNV challenge.

166 tention in vivo in the brain correlated with viral burden in the brain and cerebrospinal fluid, and w

167 , only CCL7 deficiency resulted in increased viral burden in the brain and enhanced mortality.

168 As no difference in viral burden in the brain or spinal cord was observed af

169 +) CD8(+) T-cell trafficking, an increase in viral burden in the brain, and enhanced morbidity and mo

170 increased WNV-infected PMN infiltration and viral burden in the brain, which was coupled to increase

171 h does not influence either viral tropism or viral burden in the brain.

172 ugh this may reflect merely a higher overall viral burden in the brain.

173 enhances WNV mortality in mice and increases viral burden in the brain.

174 nd compromised T-cell mitogenesis, increased viral burden in the bursae of IBDV-infected chickens.

175 ncy of perforin molecules resulted in higher viral burden in the CNS and increased mortality after WN

176 Results indicate that SAG treatment reduced viral burden in the CNS immediately after HIV transmissi

177 f a neutralizing monoclonal antibody reduced viral burden in the lung and mitigated inflammation and

178 ith prior OC43 exposure results in increased viral burden in the lung but no change in virus-induced

179 t reduction in HIV-1 replication and overall viral burden in the macrophage culture.

180 ron infection in the lung and suppression of viral burden in the nares at 6 weeks after the final boo

181 High viral burden in the onset of infection drives responding

182 variants, with limited weight loss and lower viral burden in the upper and lower respiratory tracts.

183 are significantly associated with a reduced viral burden in the upper respiratory tract.

184 al lymph-node biopsies for the assessment of viral burden in these tissues.

185 itative technique was developed to determine viral burden in two important cellular compartments in l

186 howed less weight loss and 10-100-fold lower viral burden in upper and lower respiratory tracts.

187 ngly sensitive and precise assays to measure viral burden in various tissues and body fluids.

188 trations where ivermectin reduced SARS-CoV-2 viral burden in vitro, ivermectin decreased cell viabili

189 asts was associated with a downmodulation in viral burden in vivo.

190 ed YFV infection in cell culture and reduced viral burden in vivo.

191 lly reduced viral replication and infectious viral burdens in a frog kidney cell line and in tadpoles

192 nst FV3 infection, decreasing the infectious viral burdens in both cases.

193 s from weight loss and substantially reduces viral burdens in both lower and upper airways compared t

194 ad (sevenfold) as well as in early set-point viral burdens in both plasma and lymphoid tissues (10-fo

195 nt to FDC may offer new avenues for reducing viral burdens in infected individuals.

196 pDCs in Mavs(-/-) mice resulted in increased viral burdens in joint and muscle tissues, suggesting th

197 Relatively small differences in viral burdens in peripheral tissues of TNF-R1(-/-) mice

198 High viral burdens in target tissues were associated with org

199 ice survived CHIKV infection and bore higher viral burdens in the heart tissues than the wild-type (W

200 The viral burdens in the infected rgp120 vaccine recipients

201 Analogously, morbidity, mortality, and viral burdens in tissues were identical between Ifit1(-/

202 inhibition attenuates both inflammation and viral burden, in infected chips with breathing motions.

203 es in RMs and humans than in SMs; and (4) LT viral burden, including follicular dendritic cell deposi

204 accinations and against symptomatic and high viral burden infections, and with no evidence of a diffe

205 th A. fumigatus had increased fungal burden, viral burden, inflammation, and mortality compared with

206 High viral burden is coincident with inadequate adaptive immu

207 can be infected, but the distribution of the viral burden is differentially allocated to lymphocyte a

208 After a hamster is treated with MAb 201, its viral burden is reduced by 102.4-103.9 50% tissue-cultur

209 (PCR)-positive cases) with symptoms or high viral burden is reduced with the B.1.617.2 variant (abso

210 e popular approach to summarizing historical viral burden is the area under a time-VL curve (AUC).

211 t CD8(+) T cell response in the face of high viral burden is vital for host survival.

212 enge markedly impaired viral replication and viral burdens, it only transiently extended tadpole surv

213 However, without knowledge of differences in viral burdens, it remains unclear whether NK cells are e

214 ing SARS-CoV-2 infection with respect to the viral burden, level of tissue necrosis, and immunologica

215 protein on Tregs can lead to a reduction in viral burden, limit T cell exhaustion, and enhance gp33-

216 1 diversification could be related to higher viral burdens, manifestations of disease, and/or dual in

217 Together, this suggests that viral burden may be a risk factor for dementia.

218 years viremia, a novel measure of cumulative viral burden, may provide prognostic information beyond

219 determine whether cerebrospinal fluid (CSF) viral burden measurements can assist in the evaluation o

220 worse prognosis, suggesting that persistent viral burden might drive inflammation in the pathogenesi

221 , a wild-derived strain, developed high lung viral burdens, more severe lung pathology than seen in o

222 ly active antiretroviral therapy in reducing viral burden, neurologic disease associated with HIV-1 i

223 e purpose of this study was to determine the viral burden of HIV-1 in the lungs by comparing HIV-1 RN

224 ransplant recipients may have prolonged high viral burden of SARS-CoV-2.

225 not correlate with the clinical severity or viral burden of secondary DV infection.

226 However, the impact of viral burden on these outcomes is unknown.

227 have high mortality rates, but the impact of viral burden on these outcomes is unknown.

228 ked to increased necrosis markers but not to viral burden or immune system response.

229 ient mouse lines, we found no changes in the viral burden or tissue distribution of MNV in both an ac

230 ere no significant differences in the tissue viral burdens or the kinetics of viral spread.

231 We analyzed the association between baseline viral burden (plasma nucleocapsid antigen [N-Ag] level a

232 ce, intranasal delivery of MSC(ACE2) reduced viral burden, preserved ACE2 expression, limited neutrop

233 d lethality after WNV infection and elevated viral burden primarily in the brain, even though little

234 y-three percent of the mice with this latent viral burden reactivated in vivo following hyperthermic

235 sociated with a significant elevated risk of viral burden rebound (ARR: -1.08% (-1.55%, -0.46%)), alt

236 nical outcomes and/or lead to post-treatment viral burden rebound due to inadequate viral clearance d

237 ion of the Treg response as a result of high viral burden regulates late-stage SLEC number.

238 he hypothesis that HIV-1 infection induces a viral burden-related, global activation of the immune sy

239 Although viral burden relates to disease severity, pathogenesis i

240 Analysis of viral burden revealed that the DIO variable did not impa

241 esponses (IL-6, C-reactive protein), overall viral burden (SARS-CoV-2 spike protein), and specific im

242 ning, somewhat less so to a semiquantitative viral burden score based on numbers of HIV gp41-immunore

243 V-1 envelope protein from a donor with a low viral burden, stable CD4(+) T-lymphocyte counts, and lit

244 k of any acute toxicity or adverse effect on viral burden suggests that therapy with antiviral CTLs d

245 tibody deficiency in the setting of a tissue viral burden suggests that using an antibody as a therap

246 m, we have evaluated longitudinal changes in viral burden, T-cell subsets, and mucosal gene expressio

247 te counts were higher (P < 0.001) and plasma viral burdens tended to be lower (P = 0.08) in HIV-infec

248 at received adjuvanted vaccines showed lower viral burden than the control or unadjuvanted vaccine gr

249 ptible to WNV infection and develop a higher viral burden than wild-type (WT) mice.

250 l confronts the immune system with a chronic viral burden that may involve immune cells themselves an

251 s a less expensive alternative for measuring viral burden that quantifies RT enzyme activity in clini

252 ing infection of Ctx(-) mice, while they had viral burdens that were identical to those of WT animals

253 HIV-1 RNA levels in plasma may influence CSF viral burden, these variables were examined as potential

254 IFNalpha therapy is associated with reduced viral burden, this cytokine also mediates immune dysfunc

255 RP v1.7 did not detect HAdV with either low viral burden (threshold cycle values of >30) or nonrespi

256 protection from IAV in mice, independent of viral burden through host tolerance pathways.

257 ts who are infected with HCV by reducing the viral burden through specific targeting and cleavage of

258 eased IFN-I production and better control of viral burden upon LCMV infection but show exacerbated HS

259 se activity, but also leads to increased HCV viral burden via alterations in immunologic viral survei

260 Although no difference in viral burden was detected in peripheral tissues, greater

261 ne activation overall, while the response to viral burden was gauged with serum level of spike protei

262 more vulnerable to lethal WNV infection, the viral burden was greater only within the CNS, particular

263 N-alpha/betagammaR(-/-) mice even though the viral burden was heavy.

264 The BAL viral burden was higher than plasma HIV-1 in tuberculosi

265 ainst ZIKV infection in the ovary, as higher viral burden was measured in CD8-/- and TCRbetadelta-/-

266 During peak loss of CD4+ cells, high viral burden was observed, suggesting that loss of CD4+

267 Viral burden was quantified by a microculture technique

268 serum markers of immunologic activation, and viral burden were assessed in 75 human immunodeficiency

269 Levels of viral burden were compared across risk group and gender

270 Moreover, no significant differences in viral burden were observed in hACE2 KI mice infected wit

271 iring high concentrations of Ag for reducing viral burden when adoptively transferred into SCID mice.

272 e P receptor expression, showed an increased viral burden when compared with syngeneic C57BL/6 mice.

273 es exhibited higher survival rates and lower viral burdens when reared on P. lanceolata compared to B

274 ansfer of ZIKV-immune CD8(+) T cells reduced viral burdens, whereas their depletion led to higher tis

275 ypes in Nigeria exhibit long periods of high viral burden, which can contribute to increased transmis

276 Thus, type I IFNs critically regulate early viral burden, which serves as an innate checkpoint deter

277 High viral burden with EBV was associated with the developmen

278 le factors involved in Zika disease, linking viral burden with increased neurological disease severit

279 Children aged 1>5 years had a higher total viral burden with prolonged virus shedding and had an in

280 Children aged 1-5 years had a higher total viral burden with prolonged virus shedding and had an in

281 link multiple disease parameters, including viral burden, with neurological disease severity, weight

282 on of macrophages and T cells to the overall viral burden within lymphoid tissue.

283 ) resulted in increased survival and reduced viral burden within the brain and liver compared to thos

284 ty that correlated with a >3 log increase in viral burden within the brains as compared with control

285 mice, an infection model that exhibits high viral burden within the central nervous system.

286 eta-KO mice displayed minimal differences in viral burdens within the ankle or at distal sites and in